DOJ Fraud Section Closes Research Misconduct Inquiry Against Cassava Sciences
Summary
Cassava Sciences announced the closure of the U.S. Department of Justice Fraud Section's inquiry into allegations of research misconduct, removing a major legal and reputational risk.
Key Events
-
DOJ Inquiry Closed
The U.S. Department of Justice Fraud Section has formally closed its inquiry into Cassava Sciences regarding allegations of research misconduct.
-
Prior Indictment Dismissed
The inquiry was related to an indictment in United States v. Wang, which was previously dismissed with prejudice by the DOJ on October 23, 2025.
-
SEC Settlement Previously Reached
This resolution follows a settlement with the U.S. Securities and Exchange Commission (SEC) in September 2024 regarding negligence-based disclosure charges, concluding all major investigations into the company.
Analysis
The closure of the U.S. Department of Justice Fraud Section's inquiry into allegations of research misconduct removes a significant legal and reputational overhang for Cassava Sciences. For a biotechnology company, such investigations can severely impact investor confidence, partnership opportunities, and the progression of clinical trials. This definitive resolution, following the prior dismissal of an indictment and settlement with the SEC, substantially de-risks the company's profile and allows management to fully focus on its core drug development activities, particularly for TSC-related epilepsy.
At the time of this filing, SAVA was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.9M. The 52-week trading range was $1.15 to $4.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.